MedTrace Logo

Molecular Markes of Fibrosis of Endometriosis and Their Use in Predicting Disease Severity

NCT06020482 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-08-31

No results posted yet for this study

Summary

The primary aim of the project is to analyse gene expression in individual types of ectopic endometrium (ovarian endometriosis, peritoneal endometriosis, deep infiltrating endometriosis) and compare it with gene expression in eutopic endometrium. The analysis focuses on the identification of genes with significantly increased expression in each type of ectopic endometrium and comparison of their expression with the degree of disease, ovarian reserve and clinical manifestations of the disease (pain, infertility).

Conditions

  • Molecular Markers of Fibrosis of Single Types of Endometriosis and Their Use in Predicting Disease Severity

Interventions

OTHER

Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity

The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.

Sponsors & Collaborators

  • General University Hospital, Prague

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06020482 on ClinicalTrials.gov